Oppenheimer Initiates Outperform Coverage on Palisade Bio with $8 Price Target
Strong bullish case for its oral IBD therapy ahead of Phase 2 data.
/ 220 items
#andre↓
Reddit Shares Plunge as It Considers Ending Google AI Partnership
Wells Fargo warns of revenue pressure but sees possible long-term upside for the platform.
AMD Invests Up to $5 Billion in Anthropic While Securing Huge GPU Contract
Anthropic secures up to 2GW of AMD Instinct MI450 GPUs and a $5B strategic investment from AMD. The deal strengthens AMD’s position in AI infrastructure against Nvidia while powering Claude’s growth.
Arrowhead’s Plozasiran Cuts Acute Pancreatitis Risk by Up to 100% in Phase 3 Severe Hypertriglyceridemia Trials
Arrowhead plans sNDA filing by end of 2026.
Repligen Acquires BioLife Solutions for $1.5 Billion to Strengthen Cell and Gene Therapy Leadership
Repligen to acquire BioLife Solutions in a $1.5B cash-and-stock deal to strengthen its position in the fast-growing cell and gene therapy market. Expected to close Q4 2026.
Dyne Therapeutics Prices Upsized $375 Million Public Offering to Fuel Muscle Disease Pipeline
Dyne Therapeutics announced the pricing of an upsized $375 million public stock offering at $20.50 per share to advance DMD and DM1 programs and extend cash runway into 2029.